Beste CAR-T-Zelltherapie Hämatologe-Onkologen in der Türkei - TOP -9 Ärzte

Assoc. Prof. Ali Eser received his medical education at Uludağ University Faculty of Medicine; He completed his internal medicine residency training at Istanbul Training and Research Hospital and his hematology residency training at Marmara University.

Afterward, he completed his compulsory service at Marmara University Hematology Clinic, firstly at Çanakkale University and then at Bezmialem Vakıf University. He served as a lecturer. After working as a hematology specialist and assistant physician in charge of the adult bone marrow transplant unit for 2 years at Hisar Intercontinental Hospital, he worked as a lecturer at Bezmialem Vakıf University and in the adult bone marrow transplant unit at Istanbul Yeniyüzyıl University, and finally for 1 year. He worked as the responsible physician of the adult bone marrow transplant unit at Liv Hospital Gaziantep Hospital for some time. He received the title of associate professor in March 2022.

• Dr. Serdar Bedii Omay ist auf die fortgeschrittene CAR-T-Zelltherapie spezialisiert.
• Zu den innovativen CAR-T-Zellmethoden gehören Leukapherese, Zelltechnik und Infusion.
• Internationale Ausbildung, darunter Molekulare Hämatologie in Japan.
• Besitzt eine Zertifizierung in Innere Medizin und Hämatologie.
• Mitglied renommierter hämatologischer Gesellschaften, Experte für Knochenmarktransplantation.
• Bietet Fernkonsultationen für Patienten, die eine CAR-T-Zelltherapie wünschen.
• Spricht Türkisch und Englisch und erleichtert so die internationale Patientenkommunikation.

• Dr. Birol Baytan ist auf die innovative CAR-T-Zelltherapie bei Krebserkrankungen im Kindesalter spezialisiert.
• Führt eine CAR-T-Zelltherapie mit Techniken wie Leukapherese, Zelltechnik und Infusion durch.
• Internationale Praxis in der Türkei, führend in der pädiatrischen Knochenmarktransplantation.
• Besitzt Zertifizierungen in pädiatrischer Hämatologie und Onkologie.
• Mitglied renommierter medizinischer Vereinigungen für Hämatologie und Kinderkrebs.
• Bietet Online-Konsultationen zur CAR-T-Zelltherapie und verbessert so den Patientenzugang.
• Fließend Türkisch und Englisch, um eine klare Kommunikation mit unterschiedlichen Patienten zu gewährleisten.

• Dr. Songul Serefhanoglu ist im ISU Medical Park auf CAR-T-Zelltherapie spezialisiert.
• Experte für hämatopoetische Stammzelltransplantation, anwendbar auf CAR-T-Zell-Methoden.
• Nutzt innovative Techniken: Genbearbeitung, Signalwegmodulation und Sicherheitsschalterdesigns.
• Internationale Ausbildung an der Hacettepe-Universität, bekannt für medizinische Fortschritte in der Türkei.
• Professorenstatus mit umfassender Forschungs- und klinischer Erfahrung in der Hämatologie.
• Verfügt über bedeutende Berufsmitgliedschaften, was auf fortgeschrittene Praxis und Kenntnisse hinweist.
• Führt Online-Konsultationen für Patienten durch, die Fachwissen in der CAR-T-Zelltherapie suchen.

Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.

His medical interests include:

Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)

Acute Leukemia

Chronic Leukemia Treatments

Hodgkin Lymphoma

Non-Hodgkin Lymphoma Treatments

Multiple Myeloma Treatments, MDS

Aplastic Anemia

ITP

TTP Treatments

Hypercoagulability

Hereditary Thrombophilia Treatments

Therapeutic Apheresis

Photopheresis

Geriatric Hematology Diseases.